Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 7 Saturday Friday Sunday Monday Tuesday Publication Only SATURDAY, JUNE 1 ST 1:15pm - 6:00pm Central Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 1:15 - 2:45pm 1:27 - 1:39pm Hall B1 Oral LBA8509 KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Mok T Jotte R CSS: Targeting KRAS in Non–Small Cell Lung Cancer 1:30 - 4:30pm Hall A Poster 4065 Validation of PD-L1 as a predictive biomarker of response in operable gastroesophageal adenocarcinoma: A meta-analysis and meta-regression of neoadjuvant chemoimmunotherapy trials. Cammarota A Cammarota A Gastrointestinal Cancer— Gastroesophageal, Pancreatic, and Hepatobiliary 1:30 - 4:30pm Hall A Poster 4084 Distinct tumor microbiome and metabolomic profiles to inform responses of patients with esophageal cancer to neoadjuvant chemoradiotherapy and immunotherapy. Lee S Kelly R Gastrointestinal Cancer— Gastroesophageal, Pancreatic, and Hepatobiliary 1:30 - 4:30pm Hall A Poster 3597 Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases. Sharma M Wang J, Patel M Gastrointestinal Cancer—Colorectal and Anal 1:30 - 4:30pm Hall A Poster 4136 NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3. Hussein M Hussein M, Paulson A Gastrointestinal Cancer— Gastroesophageal, Pancreatic, and Hepatobiliary 1:30 - 4:30pm Hall A Poster 4046 Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202. Muro K Gardner F Gastrointestinal Cancer— Gastroesophageal, Pancreatic, and Hepatobiliary 1:30 - 4:30pm Hall A Poster TPS9602 A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301). Long G McKean M Melanoma/Skin Cancers 1:30 - 4:30pm Hall A Poster TPS4212 A phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer. Hendifar A Uemura M, Chung K, Richards D Gastrointestinal Cancer— Gastroesophageal, Pancreatic, and Hepatobiliary